| Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials T Vilsbøll, M Christensen, AE Junker, FK Knop, LL Gluud Bmj 344, d7771, 2012 | 724 | 2012 |
| Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? FK Knop, T Vilsbøll, PV Højberg, S Larsen, S Madsbad, A Vølund, JJ Holst, ... Diabetes 56 (8), 1951-1959, 2007 | 354 | 2007 |
| Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity A Vrieze, C Out, S Fuentes, L Jonker, I Reuling, RS Kootte, E van Nood, ... Journal of hepatology 60 (4), 824-831, 2014 | 292 | 2014 |
| Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with … PV Højberg, T Vilsbøll, R Rabøl, FK Knop, M Bache, T Krarup, JJ Holst, ... Diabetologia 52 (2), 199, 2009 | 284 | 2009 |
| The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide—regardless of … T Vilsbøll, FK Knop, T Krarup, A Johansen, S Madsbad, S Larsen, ... The Journal of Clinical Endocrinology & Metabolism 88 (10), 4897-4903, 2003 | 225 | 2003 |
| Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes JJ Holst, FK Knop, T Vilsbøll, T Krarup, S Madsbad Diabetes Care 34 (Supplement 2), S251-S257, 2011 | 211 | 2011 |
| The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action KJ Hare, T Vilsbøll, M Asmar, CF Deacon, FK Knop, JJ Holst Diabetes 59 (7), 1765-1770, 2010 | 209 | 2010 |
| Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans M Christensen, L Vedtofte, JJ Holst, T Vilsbøll, FK Knop Diabetes 60 (12), 3103-3109, 2011 | 204 | 2011 |
| Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies S Calanna, M Christensen, JJ Holst, B Laferrere, LL Gluud, T Vilsbøll, ... Diabetologia 56 (5), 965-972, 2013 | 197 | 2013 |
| Impaired regulation of the incretin effect in patients with type 2 diabetes JI Bagger, FK Knop, A Lund, H Vestergaard, JJ Holst, T Vilsbøll The Journal of Clinical Endocrinology & Metabolism 96 (3), 737-745, 2011 | 193 | 2011 |
| 2-Oleoyl glycerol is a GPR119 agonist and signals GLP-1 release in humans KB Hansen, MM Rosenkilde, FK Knop, N Wellner, TA Diep, JF Rehfeld, ... The Journal of Clinical Endocrinology & Metabolism 96 (9), E1409-E1417, 2011 | 192 | 2011 |
| Self-expanding metal stents for colonic obstruction: experiences from 104 procedures in a single center S Meisner, M Hensler, FK Knop, F West, P Wille-Jørgensen Diseases of the colon & rectum 47 (4), 444-450, 2004 | 164 | 2004 |
| The Nkx6. 1 homeodomain transcription factor suppresses glucagon expression and regulates glucose-stimulated insulin secretion in islet beta cells JC Schisler, PB Jensen, DG Taylor, TC Becker, FK Knop, S Takekawa, ... Proceedings of the National Academy of Sciences 102 (20), 7297-7302, 2005 | 163 | 2005 |
| Inappropriate suppression of glucagon during OGTT but not during isoglycaemic iv glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus FK Knop, T Vilsbøll, S Madsbad, JJ Holst, T Krarup Diabetologia 50 (4), 797-805, 2007 | 147 | 2007 |
| Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition RS Kootte, E Levin, J Salojärvi, LP Smits, AV Hartstra, SD Udayappan, ... Cell metabolism 26 (4), 611-619. e6, 2017 | 142 | 2017 |
| Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity FK Knop, K Aaboe, T Vilsbøll, A Vølund, JJ Holst, T Krarup, S Madsbad Diabetes, Obesity and Metabolism 14 (6), 500-510, 2012 | 138 | 2012 |
| The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes A Lund, T Vilsbøll, JI Bagger, JJ Holst, FK Knop American Journal of Physiology-Endocrinology and Metabolism 300 (6), E1038-E1046, 2011 | 138 | 2011 |
| Regulation of glucagon secretion by incretins JJ Holst, M Christensen, A Lund, J De Heer, B Svendsen, U Kielgast, ... Diabetes, Obesity and Metabolism 13, 89-94, 2011 | 129 | 2011 |
| Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities A Lund, FK Knop, T Vilsbøll European journal of internal medicine 25 (5), 407-414, 2014 | 122 | 2014 |
| Twelve weeks treatment with the DPP‐4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non‐glucose induced insulin secretion in patients with … K Aaboe, FK Knop, T Vilsbøll, CF Deacon, JJ Holst, S Madsbad, T Krarup Diabetes, Obesity and Metabolism 12 (4), 323-333, 2010 | 111 | 2010 |
Professor Tina VilsbøllDirector, Center for Diabetes Research, Gentofte Hospital, University of Copenhagen, DenmarkVerified email at dadlnet.dk
